Bradley Pharmaceuticals Announces Receipt of 'Going Private' Proposal at $21.50 Per Share Establishment of Special Committee

May 29, 2007, 01:00 ET from Bradley Pharmaceuticals, Inc.

    FAIRFIELD, N.J., May 29 /PRNewswire-FirstCall/ -- Bradley
 Pharmaceuticals, Inc. (NYSE:   BDY) announced that its Board of Directors has
 received a proposal today from a group of investors led by Daniel Glassman,
 founder, President and CEO of the Company and the holder of nearly all of
 the Company's Class B common stock, to acquire all of the outstanding
 shares of Bradley common stock and Class B common stock for $21.50 per
 share in cash. According to the proposal letter, Mr. Glassman intends to
 reinvest a substantial portion of his equity ownership of the Company
 through this transaction. The proposal letter also states that Mr. Glassman
 has received indications of willingness from One Equity Partners LLC to
 provide the new cash equity and from Credit Suisse Securities (USA) LLC to
 underwrite the debt financing. A copy of the text of the proposal letter to
 the Bradley Board of Directors is set forth below in this release.
     The Bradley Board of Directors has formed a special committee of
 independent directors to consider the Company's strategic alternatives,
 including Mr. Glassman's proposal. The committee is composed of the three
 directors that are elected by the holders of the Company's common stock,
 Mr. Seth W. Hamot, interim non-executive Chairman of the Board, Mr. Douglas
 E. Linton, Chairman of the Nominating and Corporate Governance Committee,
 and Mr. William J. Murphy, Chairman of the Audit Committee. The special
 committee will retain independent financial advisors and legal counsel to
 assist it in its work. There can be no assurance that any definitive offer
 will be made, that any agreement will be executed or that this or any other
 transaction will be approved or consummated.
     In response to the proposal, Mr. Hamot said, "The Board will review Mr.
 Glassman's proposal thoroughly but I caution Bradley stockholders and
 others considering trading in its securities that we have only just
 received the proposal and that no decisions have been made by the Board of
 Directors with respect to the Company's response to this "going private"
     * * *
     May 29, 2007
     Bradley Pharmaceuticals, Inc.
     Special Committee of the Board
     383 Route 46 West
     Fairfield, NJ  07004
     Further to my prior discussions with the Board of Directors, I am
 pleased to propose to acquire by merger, for a cash purchase price of
 $21.50 per share, all of the outstanding shares of common stock and Class B
 common stock of Bradley Pharmaceuticals, Inc. (the "Company").
     I believe that this proposal offers compelling value and is in the best
 interest of the Company and all of its shareholders, as well as its
 management and employees. The offer price represents a substantial premium
 of approximately 16.6% over the Company's closing share price as of May 25,
     I would remain CEO immediately following the transaction, and expect
 the Company's senior management team would continue to lead the Company
 into the future with me.
     I currently expect that I will reinvest a substantial portion of my
 equity ownership of the Company through this transaction. I expect that the
 transaction would be financed through a combination of roll-over equity
 provided by myself and others and new cash equity and debt financing. With
 your approval, I have had further discussions with One Equity Partners LLC
 and they have indicated a willingness to provide the new cash equity. I
 have also continued discussions with Credit Suisse Securities (USA) LLC and
 they have indicated a willingness to underwrite the debt financing.
     I am prepared to move very quickly to negotiate a transaction with the
 Special Committee and its advisers, and believe that my familiarity with
 the Company and its operations will allow us to finalize definitive
 documentation on an accelerated basis. I expect to provide shortly a
 proposed merger agreement that we would be willing to enter into. In
 anticipation of doing so, I would expect that One Equity and Credit Suisse
 would be given access to other members of management and additional due
 diligence materials. With the cooperation of the Company, I expect to be in
 a position to execute definitive documents within a few weeks.
     No binding obligation on the part of the undersigned or the Company
 shall arise with respect to the proposal or any transaction unless and
 until a definitive merger agreement satisfactory to me and recommended by
 the Special Committee and approved by the Board of Directors is executed
 and delivered. I look forward to discussing this proposal with you further
 in the near future.
     Daniel Glassman
     About Bradley Pharmaceuticals, Inc.
     Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
 pharmaceutical company and markets to niche physician specialties in the
 U.S. and international markets. Bradley's success is based upon its core
 strengths in marketing and sales, which enable the company to Commercialize
 brands that fill unmet patient and physician needs; Develop new products
 through life cycle management; and In-License phase II and phase III drugs
 with long-term intellectual property protection that upon approval leverage
 Bradley's marketing and sales expertise to increase shareholder value.
 Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in
 therapies for dermatology and podiatry; Kenwood Therapeutics, providing
 gastroenterology, OBGYN, respiratory and other internal medicine brands;
 and A. Aarons, which markets authorized generic versions of Doak and
 Kenwood therapies.
     Safe Harbor for Forward-Looking Statements --
     This release contains "forward-looking statements" within the meaning
 of the Private Securities Litigation Reform Act of 1995. Forward-looking
 statements include statements that address activities, events or
 developments that Bradley expects, believes or anticipates will or may
 occur in the future. Forward-looking statements are subject to numerous
 risks and uncertainties, many of which are beyond Bradley's control. Actual
 results may differ materially from those projected. These risks and
 uncertainties include those described from time to time in Bradley's SEC
 filings, including its Annual Report on Form 10-K and its most recent
 Quarterly Report on Form 10-Q. Except as required by law, Bradley
 undertakes no obligation to publicly update any forward-looking statement
 in this press release, including any information related to the special
 committee and its work, whether as a result of new information, future
 events or otherwise.

SOURCE Bradley Pharmaceuticals, Inc.